{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:41:25Z","timestamp":1791848485299,"version":"4.3.4"},"reference-count":52,"publisher":"Elsevier BV","issue":"38","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"am","delay-in-days":387,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015691","name":"NIAID DMID","doi-asserted-by":"publisher","award":["HHS-N272201400053C"],"award-info":[{"award-number":["HHS-N272201400053C"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.vaccine.2023.07.061","type":"journal-article","created":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T23:14:59Z","timestamp":1690758899000},"page":"5592-5602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["An Advax-CpG55.2 adjuvanted recombinant hemagglutinin vaccine provides immunity against H7N9 influenza in adult and neonatal mice"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2872-8621","authenticated-orcid":false,"given":"Yoshikazu","family":"Honda-Okubo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7472-3864","authenticated-orcid":false,"given":"Isaac G.","family":"Sakala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greiciely","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Bart","family":"Tarbet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett L.","family":"Hurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-5245","authenticated-orcid":false,"given":"Nikolai","family":"Petrovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.07.061_b0005","doi-asserted-by":"crossref","first-page":"2155072","DOI":"10.1080\/22221751.2022.2155072","article-title":"Alarming situation of emerging H5 and H7 avian influenza and effective control strategies","volume":"12","author":"Shi","year":"2023","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.vaccine.2023.07.061_b0010","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a038620","article-title":"The epidemiology, virology, and pathogenicity of human infections with avian influenza viruses","volume":"11","author":"Wang","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.vaccine.2023.07.061_b0015","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1017\/S0950268815001570","article-title":"The pandemic potential of avian influenza A(H7N9) virus: a review","volume":"143","author":"Tanner","year":"2015","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2023.07.061_b0020","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4161\/hv.2.1.2554","article-title":"Vaccine development for an imminent pandemic: why we should worry, what we must do","volume":"2","author":"Fedson","year":"2006","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2023.07.061_b0025","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1586\/erv.11.24","article-title":"Insect cell technology is a versatile and robust vaccine manufacturing platform","volume":"10","author":"Mena","year":"2011","journal-title":"Exp Rev Vacc"},{"key":"10.1016\/j.vaccine.2023.07.061_b0030","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1016\/j.vaccine.2013.08.064","article-title":"Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5\/Indonesia\/05\/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant","volume":"31","author":"Treanor","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.07.061_b0035","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1473-3099(04)01105-3","article-title":"Confronting the avian influenza threat: vaccine development for a potential pandemic","volume":"4","author":"Stephenson","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.07.061_b0040","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1016\/j.vaccine.2015.09.030","article-title":"Advax, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety","volume":"33","author":"Petrovsky","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.07.061_b0045","doi-asserted-by":"crossref","first-page":"1105655","DOI":"10.3389\/fimmu.2023.1105655","article-title":"Review: current trends, challenges, and success stories in adjuvant research","volume":"14","author":"Singleton","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2023.07.061_b0050","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1016\/j.vaccine.2012.06.021","article-title":"Advax, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses","volume":"30","author":"Honda-Okubo","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.07.061_b0055","doi-asserted-by":"crossref","first-page":"6242","DOI":"10.1016\/j.vaccine.2011.06.078","article-title":"Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets","volume":"29","author":"Layton","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.07.061_b0060","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/978-1-4939-3387-7_14","article-title":"Development of a SARS coronavirus vaccine from recombinant spike protein plus delta inulin adjuvant","volume":"1403","author":"McPherson","year":"2016","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2023.07.061_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/v11030212","article-title":"Efficacy of an adjuvanted middle east respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas","volume":"11","author":"Adney","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2023.07.061_b0070","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1016\/j.vaccine.2021.07.087","article-title":"Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection","volume":"39","author":"Li","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.07.061_b0075","article-title":"An advax-adjuvanted inactivated cell-culture derived Japanese encephalitis vaccine induces broadly neutralising anti-flavivirus antibodies, robust cellular immunity and provides single dose protection","volume":"9","author":"Komiya","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.07.061_b0080","doi-asserted-by":"crossref","first-page":"10324","DOI":"10.1128\/JVI.00480-13","article-title":"An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody","volume":"87","author":"Petrovsky","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.07.061_b0085","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms10051034","article-title":"Enhanced immunogenicity of inactivated dengue vaccines by novel polysaccharide-based adjuvants in mice","volume":"10","author":"Wu","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.vaccine.2023.07.061_b0090","doi-asserted-by":"crossref","first-page":"7446","DOI":"10.1016\/j.vaccine.2021.10.075","article-title":"Novel adjuvants enhance immune responses elicited by a replication-defective human cytomegalovirus vaccine in nonhuman primates","volume":"39","author":"Li","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.07.061_b0095","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1016\/j.vaccine.2021.08.050","article-title":"A truncated glycoprotein G vaccine formulated with Advax-CpG adjuvant provides protection of mice against genital herpes simplex virus 2 infection","volume":"39","author":"Gorander","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.07.061_b0100","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1099\/jgv.0.000863","article-title":"DNA prime\/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant","volume":"98","author":"Menon","year":"2017","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2023.07.061_b0105","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens10050500","article-title":"Advax-CpG adjuvant provides antigen dose-sparing and enhanced immunogenicity for inactivated poliomyelitis virus vaccines","volume":"10","author":"Honda-Okubo","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2023.07.061_b0110","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1016\/j.vaccine.2020.05.009","article-title":"Adjuvant selection impacts the correlates of vaccine protection against Ebola infection","volume":"38","author":"Stronsky","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.07.061_b0115","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1016\/j.vaccine.2016.05.071","article-title":"Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax delta inulin adjuvant","volume":"34","author":"Gordon","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.07.061_b0120","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1016\/j.vaccine.2014.09.034","article-title":"Immunogenicity and safety of Advax, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study","volume":"32","author":"Gordon","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.07.061_b0125","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.cmi.2022.04.004","article-title":"Safety and immunogenicity of SpikoGen(R), an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations","volume":"28","author":"Tabarsi","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"504\u201313","key":"10.1016\/j.vaccine.2023.07.061_b0130","first-page":"e16","article-title":"Randomized controlled trial demonstrating the benefits of delta inulin adjuvanted immunotherapy in patients with bee venom allergy","volume":"144","author":"Heddle","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2023.07.061_b0135","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.1016\/j.vaccine.2012.06.009","article-title":"Randomized clinical trial of immunogenicity and safety of a recombinant H1N1\/2009 pandemic influenza vaccine containing Advax polysaccharide adjuvant","volume":"30","author":"Gordon","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.07.061_b0140","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nature12392","article-title":"Characterization of H7N9 influenza A viruses isolated from humans","volume":"501","author":"Watanabe","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.07.061_b0145","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/QCO.0b013e3283607a58","article-title":"Maternal immunization as a strategy to decrease susceptibility to infection in newborn infants","volume":"26","author":"Lindsey","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.07.061_b0150","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41586-020-2918-0","article-title":"Age-specific mortality and immunity patterns of SARS-CoV-2","volume":"590","author":"O'Driscoll","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.07.061_b0155","doi-asserted-by":"crossref","first-page":"e69586","DOI":"10.1371\/journal.pone.0069586","article-title":"Age-specific mortality during the 1918 influenza pandemic: unravelling the mystery of high young adult mortality","volume":"8","author":"Gagnon","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.07.061_b0160","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.coi.2013.07.005","article-title":"Correlates of protection against influenza infection in humans\u2013on the path to a universal vaccine?","volume":"25","author":"Li","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2023.07.061_b0165","doi-asserted-by":"crossref","first-page":"e80034","DOI":"10.1371\/journal.pone.0080034","article-title":"Mechanisms of hemagglutinin targeted influenza virus neutralization","volume":"8","author":"Brandenburg","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.07.061_b0170","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.vaccine.2019.01.086","article-title":"Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production","volume":"37","author":"Herrera-Rodriguez","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.07.061_b0175","first-page":"1","article-title":"Panblok-H1+advax H1N1\/2009pdm vaccine: Insights into rapid development of a delta inulin adjuvanted recombinant pandemic influenza vaccine","volume":"13","author":"Honda-Okubo","year":"2017","journal-title":"Hum Vacc Immunother"},{"key":"10.1016\/j.vaccine.2023.07.061_b0180","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.biologicals.2009.02.014","article-title":"FluBlok, a next generation influenza vaccine manufactured in insect cells","volume":"37","author":"Cox","year":"2009","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2023.07.061_b0185","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cmi.2022.09.001","article-title":"Evaluating the efficacy and safety of SpikoGen(R), an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial","volume":"29","author":"Tabarsi","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2023.07.061_b0190","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.07.061_b0195","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.0818-9641.2004.01272.x","article-title":"Vaccine adjuvants: current state and future trends","volume":"82","author":"Petrovsky","year":"2004","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2023.07.061_b0200","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa1608862","article-title":"Efficacy of recombinant influenza vaccine in adults 50 years of age or older","volume":"376","author":"Dunkle","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.07.061_b0205","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/07388551.2017.1416577","article-title":"Impact of host cell line choice on glycan profile","volume":"38","author":"Goh","year":"2018","journal-title":"Crit Rev Biotechnol"},{"key":"10.1016\/j.vaccine.2023.07.061_b0210","doi-asserted-by":"crossref","first-page":"e4312","DOI":"10.1093\/cid\/ciaa1352","article-title":"Comparison of A(H3N2) neutralizing antibody responses elicited by 2018\u20132019 season quadrivalent influenza vaccines derived from eggs, cells, and recombinant hemagglutinin","volume":"73","author":"Wang","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.07.061_b0215","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.vaccine.2012.01.016","article-title":"Recombinant protein vaccines produced in insect cells","volume":"30","author":"Cox","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.07.061_b0220","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1016\/j.vaccine.2015.07.051","article-title":"Advax delta inulin adjuvant overcomes immune immaturity in neonatal mice thereby allowing single-dose influenza vaccine protection","volume":"33","author":"Honda-Okubo","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.07.061_b0225","doi-asserted-by":"crossref","unstructured":"Eichinger KM, Kosanovich JL, Lipp M, Empey KM, Petrovsky N. Strategies for active and passive pediatric RSV immunization. Ther Adv Vaccines Immunother 2021;9:2515135520981516.","DOI":"10.1177\/2515135520981516"},{"key":"10.1016\/j.vaccine.2023.07.061_b0230","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1080\/1744666X.2019.1642748","article-title":"Neonatal vaccine effectiveness and the role of adjuvants","volume":"15","author":"Sakala","year":"2019","journal-title":"Exp Rev Clin Immunol"},{"key":"10.1016\/j.vaccine.2023.07.061_b0235","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22010214","article-title":"A review of murine cytomegalovirus as a model for human cytomegalovirus disease-do mice lie?","volume":"22","author":"Fisher","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.vaccine.2023.07.061_b0240","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1016\/j.vaccine.2022.04.041","article-title":"Covax-19\/Spikogen(R) vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters","volume":"40","author":"Li","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.07.061_b0245","article-title":"An Advax-CpG55.2 adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge","author":"Honda-Okubo","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.07.061_b0250","doi-asserted-by":"crossref","DOI":"10.1111\/imm.13661","article-title":"Ability of SpikoGen(R), an Advax-CpG adjuvanted recombinant spike protein vaccine, to induce cross-neutralising antibodies against SARS-CoV-2 variants","author":"Honda-Okubo","year":"2023","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2023.07.061_b0255","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/imm.13540","article-title":"Immunogenicity and safety of SpikoGen(R), an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: a randomized placebo-controlled trial","volume":"167","author":"Tabarsi","year":"2022","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2023.07.061_b0260","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/glycob\/cwq201","article-title":"Delta inulin: a novel, immunologically active, stable packing structure comprising beta-D-[2 -> 1] poly(fructo-furanosyl) alpha-D-glucose polymers","volume":"21","author":"Cooper","year":"2011","journal-title":"Glycobiology"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23008927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23008927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:59:38Z","timestamp":1778507978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23008927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":52,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0264410X23008927"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.07.061","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Advax-CpG55.2 adjuvanted recombinant hemagglutinin vaccine provides immunity against H7N9 influenza in adult and neonatal mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.07.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}